Vorhofflimmern – Was ist bei chronischer Nierenerkrankung und Hämodialyse zu beachten?

Was ist neu?

Scores zur Risikoeinschätzung Die chronische Nierenerkrankung (CKD) ist eine häufige Komorbidität bei Vorhofflimmern, wobei der CHA2DS2-VASc-Score bei höhergradiger CKD nicht validiert ist und bei Dialysepatienten nur einen geringen prädiktiven Wert aufweist.

Risikoreduktion Nach den aktuellen Empfehlungen der European Society of Cardiology (ESC) sind Nicht-Vitamin-K-antagonistische Orale Antikoagulanzien (NOAK) einer Vitamin-K-Hemmung vorzuziehen. Aufgrund der teilweisen renalen Elimination von NOAK ist die Dosis bei CKD anzupassen. Mehrere Studien deuten inzwischen auf ein akzeptables Sicherheitsprofil von NOAKs bei CKD hin, wobei größere randomisierte Studien nach wie vor fehlen. Die Ergebnisse von prospektiven Studien mit einem Placebo-Behandlungsarm, d.h. ohne Antikoagulationstherapie, sind noch ausstehend.

Vorhofohrverschluss bei Kontraindikationen Sollten Kontraindikationen für eine antithrombotische Therapie vorliegen, kann ein Vorhofohrverschluss diskutiert werden. Die Wirksamkeit und Sicherheit des Vorhofohrverschlusses muss jedoch noch besser evaluiert werden.

Abstract

CKD is a common comorbidity in patients with atrial fibrillation. The CHA2DS2-VASc score is not validated in patients with severe CKD and has a low predictive value in dialysis patients. As NOACs are partly eliminated by the kidneys the dosage has to be adapted in CKD. Recent studies indicate an acceptable safety profile for NOACs in CKD. However, larger randomized studies are still lacking. The results from prospective studies with placebo i.e., no anticoagulation therapy, are pending.

Schlüsselwörter

Vorhofflimmern - chronischer Nierenerkrankung - Hämodialyse - Risiko-Scores - NOAK - Vitamin-K-Antagonist

Keywords

atrial fibrillation - chronic kidney disease - hemodialysis - risk scores - NOAC - Vitamin K antagonist

Publication History

Article published online:
23 May 2024

• Literatur

• 1 Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
• 2 Buiten MS, de Bie MK, Rotmans JI. et al. The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Heart 2014; 100 (09) 685-690
• 3 de Jong Y, Ramspek CL, van der Endt VHW. et al. A systematic review and external validation of stroke prediction models demonstrates poor performance in dialysis patients. J Clin Epidemiol 2020; 123: 69-79
• 4 Law MM, Tan SJ, Wong MCG. et al. Atrial Fibrillation in Kidney Failure: Challenges in Risk Assessment and Anticoagulation Management. Kidney Med 2023; 5 (09) 100690
• 5 Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?. Thromb Haemost 2015; 113 (06) 1165-1169
• 6 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146 (12) 857-867
• 7 Joglar JA, Chung MK, Armbruster AL. et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2024; 149 (01) e1-e156
• 8 Turakhia MP, Blankestijn PJ, Carrero JJ. et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J 2018; 39 (24) 2314-2325
• 9 Coleman CI, Kreutz R, Sood NA. et al. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. Am J Med 2019; 132 (09) 1078-1083
• 10 Siontis KC, Zhang X, Eckard A. et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States [published correction appears in Circulation. 2018 Oct 9;138(15):e425]. Circulation 2018; 138 (15) 1519-1529
• 11 Wetmore JB, Weinhandl ED, Yan H. et al. Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study. Am J Kidney Dis 2022; 80 (05) 569-579.e1
• 12 Calderon JM, Martinez F, Fernandez A. et al. Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status. Sci Rep 2022; 12 (01) 6123
• 13 De Vriese AS, Caluwé R, Van Der Meersch H. et al. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. J Am Soc Nephrol 2021; 32 (06) 1474-1483
• 14 Reinecke H, Engelbertz C, Bauersachs R. et al. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Circulation 2023; 147 (04) 296-309
• 15 Pokorney SD, Chertow GM, Al-Khalidi HR. et al. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation 2022; 146 (23) 1735-1745
• 16 Mapili JAL, Lim LCS, Velando BM. et al. The safety and efficacy of direct oral anticoagulants among chronic kidney disease patients on dialysis with non-valvular atrial fibrillation: a meta-analysis. Front Cardiovasc Med 2023; 10: 1261183
• 17 Fink T, Paitazoglou C, Bergmann MW. et al. Left atrial appendage closure in end-stage renal disease and hemodialysis: Data from a German multicenter registry. Catheter Cardiovasc Interv 2023; 101 (03) 610-619
• 18 Jamal S, Mughal MS, Kichloo A. et al. Left atrial appendage closure using WATCHMAN device in chronic kidney disease and end-stage renal disease patients. Pacing Clin Electrophysiol 2022; 45 (07) 866-873